Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of “Hold” from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average rating of “Hold” from the eight analysts that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $19.40.

A number of equities research analysts have issued reports on TBPH shares. HC Wainwright downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. B. Riley Financial increased their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. Finally, JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th.

Theravance Biopharma Stock Performance

TBPH opened at $16.86 on Monday. The firm has a market cap of $869.13 million, a P/E ratio of 7.66 and a beta of 0.19. Theravance Biopharma has a 52-week low of $10.82 and a 52-week high of $21.03. The business’s fifty day moving average is $16.71 and its 200-day moving average is $17.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The company had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, research analysts predict that Theravance Biopharma will post 1.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider owned 9,174,453 shares in the company, valued at approximately $155,965,701. This trade represents a 0.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 350,011 shares of company stock valued at $6,008,309 over the last 90 days. Corporate insiders own 7.65% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several large investors have recently bought and sold shares of TBPH. Quarry LP bought a new position in Theravance Biopharma in the third quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.